GHK-Cu Doses, Routes, and Stability as Reported in Research

Concentrations and routes in the studied record

GHK-Cu dosage in the research literature spans cell culture to rodent systemic work, and none of it constitutes a human dosing recommendation. In vitro, fibroblast collagen synthesis was driven at 10^-12 to 10^-9 M, with onset at 10^-12 to 10^-11 M and a peak near 10^-9 M ^[1]. Topical cosmetic and clinical formulations have used roughly 0.05% to 2% (w/w) in creams, serums, and gels ^[4].

Rodent systemic studies used defined protocols: intraperitoneal dosing in mouse pulmonary models and milligram-per-kilogram ranges in silicosis and colitis models, plus intranasal dosing in aging and cognition studies ^[5]. The human exception is topical: the ALAVAX 5-ALA + GHK hair-loss trial applied 50 to 100 mg/mL to the scalp over six months ^[7]. Routes documented across the record include topical (cream, serum, liposome, microemulsion, hydrogel, nanofiber), intraperitoneal, intranasal, oral gavage, and intravenous/subcutaneous in rodents ^[5].

What the in-vitro dose-response actually fixes

The cell-culture numbers are the most precise figures in the GHK-Cu record, and they anchor everything else. Collagen synthesis in human fibroblasts began at 10^-12 to 10^-11 M and maximized near 10^-9 M, with no change in cell number — so the active concentration window is picomolar to nanomolar, and the effect is metabolic rather than proliferative ^[1]. The AHK-Cu analog showed follicle and dermal-papilla effects across the same 10^-12 to 10^-9 M range, with apoptosis reduction at 10^-9 M, which is consistent with a shared copper-tripeptide concentration window ^[9].

Biomaterial studies use higher working concentrations because the peptide is bound or released from a matrix rather than freely dosed: GHK-modified alginate showed no cytotoxicity from 1 to 500 ng/mL while driving VEGF secretion ^[13], and GHK-Cu scaffold coatings used a 1 mM coating solution to improve fibroblast viability ^[14]. These are formulation concentrations, not systemic doses, and they describe what the material delivers locally rather than what reaches circulation.

The human record, and what it does not cover

The human dosing record is narrow and almost entirely topical. Small placebo-controlled facial cream and serum trials (roughly n=13 to 71) reported improved skin density, firmness, fine lines, and wrinkle depth, and the 45-patient ALAVAX hair-loss trial applied a 50 to 100 mg/mL 5-ALA + GHK combination to the scalp over six months ^[4][7]. A topical wound-healing trial has been registered, but there are no completed Phase 2 or Phase 3 trials for systemic or injectable GHK-Cu ^[4].

That gap is the central caution for the dosing question. No FDA- or EMA-approved therapeutic GHK-Cu product exists by any route; topical Copper Tripeptide-1 is a legal cosmetic ingredient, while injectable and oral systemic formulations are unapproved research chemicals ^[4]. Injectable dosing protocols that circulate in community contexts have no peer-reviewed human pharmacokinetic basis, which is why this page describes only what was administered in specific species and models — never a human dose to take ^[4].

The half-life question

No rigorous human pharmacokinetic half-life for GHK-Cu has been published ^[4]. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases, and the copper-chelated complex is more stable than free GHK ^[5]. Secondary literature cites a short systemic elimination half-life on the order of one to two hours, but that figure is not a validated human parameter ^[4].

The stability difference between the two forms is the part with a clear mechanistic basis. The copper complex's very high stability constant (log K ~16.4) holds the metal tightly, which both limits pro-oxidant free-copper release and makes the chelate more robust than the bare peptide ^[5]. That is a statement about chemical stability, not a measured circulating half-life — the distinction matters because the absence of validated human Cmax, bioavailability, and tissue-distribution data is exactly the gap this digest marks as the drop-off step ^[4].

Topical application changes the time course locally. The human skin penetration study measured 97 +/- 6.6 ug/cm^2 of copper retained as a dermal depot over 48 hours, which is the mechanistic basis for prolonged local availability after a topical dose ^[10]. So the pharmacokinetic picture is split: poorly characterized systemically, depot-forming topically.

Formulation stability and incompatibilities

The GHK-Cu complex is stable because its copper stability constant is high (log K ~16.4), which limits pro-oxidant free-copper release; it is most stable near pH 5 to 6.5 at a 1:1 copper-to-peptide ratio ^[5]. The blue-violet color of a reconstituted solution indicates an intact Cu(II) complex; a brown or green shift indicates oxidation or precipitation ^[5].

The practical incompatibility is reducing agents and low-pH actives. Ascorbic acid (vitamin C) below about pH 3.5 reduces Cu(II) and breaks the complex, and AHAs, BHAs, and salicylic acid can destabilize it or compete for copper ^[5]. Free GHK's high hydrophilicity (clogP -2.24) limits passive skin penetration, which is why palmitoylation, liposomal encapsulation, ionic-liquid microemulsions, and microneedle pretreatment are studied as delivery enhancements ^[15].

Why delivery, not dose, dominates the topical story

For a topical compound this hydrophilic, the route and vehicle matter more than the nominal concentration. The human penetration study quantified the problem and the opportunity at once: copper crossed dermatomed skin at a permeability coefficient of 2.43 +/- 0.51 x 10^-4 cm/h and left a 97 +/- 6.6 ug/cm^2 dermal depot over 48 hours ^[10]. The 2025 review frames poor stratum-corneum permeability (free GHK clogP -2.24) as the central delivery challenge and reports microneedle pretreatment moved about 134 nmol of GHK through skin versus essentially none through intact skin ^[15].

The research vehicles follow from that constraint. Liposomal encapsulation, ionic-liquid microemulsions, and palmitoylation (Pal-GHK, clogP 1.14) raise lipophilicity for passive uptake ^[15], while biomaterials deliver the peptide from a matrix: a photo-crosslinkable hyaluronic-acid hydrogel with GHK nanofibers and a GHK-Cu-coated scaffold both improved fibroblast outcomes over free peptide or uncoated controls ^[12][14]. None of these is a dose in the pharmaceutical sense — they are delivery formats, and the field's open question is translation to validated human outcomes, not a milligram figure to recommend ^[4].